BeOne Medicines Showcases Early Clinical Success of Two Innovative Breast Cancer Therapies at ASCO 2025 BeOne Medicines Ltd. a global biotechnology company dedicated to developing targeted therapies for cancer, announced promising new data from two early-stage breast cancer drug candidates…
Viatris Reports Positive Phase 3 Results for MR-142, Advancing a Potential First-in-Class Treatment for Night Vision Impairment in Keratorefractive Patients Viatris Inc. a global healthcare company committed to bridging access and innovation, announced today that its investigational drug candidate MR-142…
Jazz Pharmaceuticals Reports Landmark Phase 3 Results for Zepzelca and Tecentriq Combo as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc has announced highly promising results from its global Phase 3 IMforte clinical trial, which evaluated…
Traditional Medicine Moves to the Forefront at 78th World Health Assembly, Paving the Way for Global Integration Traditional medicine—long an integral part of diverse cultures and communities across the globe—commanded unprecedented attention at the 78th World Health Assembly (WHA78), held…
FDA Grants Priority Review to Ascendis Pharma’s NDA for TransCon® CNP in Achondroplasia Treatment Ascendis Pharma A/S a biopharmaceutical company focused on developing innovative therapies for patients with serious rare diseases, announced a significant regulatory milestone today. The U.S. Food…
Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal, Expanding Rare Immunological Disease Portfolio and Deepening Immunology Pipeline In a landmark move to expand its presence in rare immunological diseases and strengthen its early-stage pipeline, French pharmaceutical giant Sanofi announced…
Novartis Highlights Kisqali’s Promise in Reducing Recurrence Risk for Younger Patients with Early Breast Cancer at ASCO 2025 At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis unveiled new insights from a subgroup analysis of its pivotal…
AstraZeneca’s Camizestrant Shows Landmark Efficacy in Advanced HR-Positive Breast Cancer with ESR1 Mutations in Phase III SERENA-6 Trial In a pivotal breakthrough for hormone receptor (HR)-positive, HER2-negative advanced breast cancer, AstraZeneca’s investigational selective estrogen receptor degrader (SERD), camizestrant, has demonstrated…
AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing the potential of its immunotherapy drug Imfinzi (durvalumab) to transform…
Roche Reports Promising Two-Year Results for Fenebrutinib in Relapsing Multiple Sclerosis, Maintaining Disease Control and Halting Disability Progression Roche has released encouraging new long-term data from its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, in the treatment of relapsing multiple…
Merck Reports Encouraging Early Data for Investigational KRAS G12C Inhibitor MK-1084 in Phase 1 Trial for Advanced Colorectal and Lung Cancers Merck known as MSD outside the United States and Canada, has announced promising early results from its ongoing KANDLELIT-001…
AbbVie and the Chicago Cubs Launch Multi-Year “Striking Out Cancer” Campaign to Support Cancer Awareness and Research In a bold and heartfelt effort to turn America’s favorite pastime into a platform for cancer advocacy, AbbVie,a global biopharmaceutical company headquartered in…